PBLS – Parabilis Medicines Inc

[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=PBLS#%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]

PBLS — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

4.44

Margin Of Safety %

Put/Call OI Ratio

0.64

EPS Next Q Diff

EPS Last/This Y

0.15

EPS This/Next Y

-0.24

Price

34.83

Target Price

41.75

Analyst Recom

Performance Q

Upside

N/A

Beta

Ticker: PBLS

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-07-14	PBLS	31.15	N/A	N/A	0
2026-07-15	PBLS	29.91	N/A	N/A	0
2026-07-16	PBLS	29.03	N/A	N/A	0
2026-07-17	PBLS	29.84	N/A	N/A	0
2026-07-20	PBLS	27.84	N/A	N/A	0
2026-07-21	PBLS	30.02	N/A	N/A	0
2026-07-22	PBLS	30.68	0.50	0.67	33
2026-07-23	PBLS	32.87	0.54	2.00	37
2026-07-24	PBLS	31.4	0.44	0.80	36
2026-07-27	PBLS	31.74	0.44	0.80	36
2026-07-28	PBLS	32.1	0.47	0.00	44
2026-07-29	PBLS	31.88	0.47	0.00	44
2026-07-30	PBLS	32.4	0.47	0.00	44
2026-07-31	PBLS	34.17	0.45	0.00	45
2026-08-03	PBLS	34.2	0.44	0.67	46
2026-08-04	PBLS	35.99	0.46	0.00	51
2026-08-05	PBLS	35.07	0.46	0.00	51
2026-08-06	PBLS	35.47	0.44	999.99	52
2026-08-07	PBLS	34.94	0.64	0.17	59
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-07-14	PBLS	31.06	-	-	-
2026-07-15	PBLS	29.91	-	-	-
2026-07-16	PBLS	28.95	-	-	-
2026-07-17	PBLS	29.63	-	-	-
2026-07-20	PBLS	27.29	-	-	-
2026-07-21	PBLS	30.12	-	-	-
2026-07-22	PBLS	30.75	-	-	-
2026-07-23	PBLS	32.80	-	-	-
2026-07-24	PBLS	31.31	-	-	-
2026-07-27	PBLS	31.82	-	-	-
2026-07-28	PBLS	32.10	-	-	-
2026-07-29	PBLS	31.60	-	-	-
2026-07-30	PBLS	32.15	-	-	-
2026-07-31	PBLS	33.99	-	-	-1.66
2026-08-03	PBLS	34.08	-	-	-1.66
2026-08-04	PBLS	34.08	-	-	-1.66
2026-08-05	PBLS	34.90	-	-	-1.66
2026-08-06	PBLS	35.59	-	-	-1.66
2026-08-07	PBLS	34.83	-	-	-1.66
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

16 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-07-14	PBLS	294.70	102.46	3.11
2026-07-15	PBLS	294.70	102.46	3.11
2026-07-16	PBLS	294.70	102.46	3.11
2026-07-17	PBLS	294.70	102.46	3.11
2026-07-20	PBLS	294.70	42.79	3.11
2026-07-21	PBLS	294.70	42.79	3.11
2026-07-22	PBLS	294.70	42.79	3.11
2026-07-23	PBLS	308.25	42.79	3.11
2026-07-24	PBLS	308.25	42.79	3.11
2026-07-27	PBLS	308.25	48.49	4.44
2026-07-28	PBLS	308.25	48.49	4.44
2026-07-29	PBLS	308.29	48.49	4.44
2026-07-30	PBLS	308.29	48.49	4.44
2026-07-31	PBLS	308.30	48.49	4.44
2026-08-03	PBLS	308.30	49.37	4.44
2026-08-04	PBLS	308.30	49.37	4.44
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

16 items 1 of 1

[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=PBLS 589 360 ]

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.24

Avg. EPS Est. Next Quarter

-0.37

Insider Transactions

308.3

Institutional Transactions

49.37

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

5.4

Max Drawdown 5-Year %

Target Price

41.75

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y

-1.66

EPS Next Y. (Est.)

-1.9

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.43

Return on Equity vs Sector %

-100

Return on Equity vs Industry %

-97.1

EPS 1 7Days Diff

-1.7

EPS 1 30Days Diff

-1.66

EBIT Estimation

[iframe https://widget.finnhub.io/widgets/recommendation?symbol=PBLS 589 450 ]

[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=PBLS 589 450 ]

No data found for PBLS

PBLS — P/E HistoricalBiotechnology

Parabilis Medicines, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 145

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.

PBLS

Latest News

—

Caricamento notizie per PBLS…

stock quote shares PBLS – Parabilis Medicines Inc Stock Price stock today

news today PBLS – Parabilis Medicines Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch PBLS – Parabilis Medicines Inc yahoo finance google finance

stock history PBLS – Parabilis Medicines Inc invest stock market

stock prices PBLS premarket after hours

ticker PBLS fair value insiders trading

ROIV – Roivant Sciences Ltd

ROIV — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

5.89

Margin Of Safety %

Put/Call OI Ratio

0.39

EPS Next Q Diff

EPS Last/This Y

-1.07

EPS This/Next Y

-0.06

Price

36.33

Target Price

41.27

Analyst Recom

1.31

Performance Q

28.47

Upside

-126.6%

Beta

1.12

Ticker: ROIV

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-07-14	ROIV	34.92	0.41	4.52	49756
2026-07-15	ROIV	34.89	0.41	0.02	49922
2026-07-16	ROIV	33.93	0.41	0.00	50026
2026-07-17	ROIV	34.52	0.41	6.67	50040
2026-07-20	ROIV	34.06	0.37	0.50	46006
2026-07-21	ROIV	34.94	0.37	0.05	46002
2026-07-22	ROIV	34.91	0.37	6.25	46011
2026-07-23	ROIV	35.12	0.38	0.14	46447
2026-07-24	ROIV	35.03	0.38	4.63	46470
2026-07-27	ROIV	34.7	0.38	0.10	46485
2026-07-28	ROIV	33.82	0.38	0.31	46482
2026-07-29	ROIV	32.86	0.38	1.36	46493
2026-07-30	ROIV	34.53	0.39	0.41	46521
2026-07-31	ROIV	33.91	0.39	0.06	46575
2026-08-03	ROIV	33.32	0.39	0.00	46574
2026-08-04	ROIV	34.61	0.39	0.18	46584
2026-08-05	ROIV	34.59	0.39	0.75	46615
2026-08-06	ROIV	35.11	0.39	0.47	46630
2026-08-07	ROIV	36.32	0.39	0.11	47260
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-07-14	ROIV	34.91	-42.2	-	-1.50
2026-07-15	ROIV	34.87	-42.2	-	-1.50
2026-07-16	ROIV	33.93	-42.2	-	-1.50
2026-07-17	ROIV	34.52	-42.2	-	-1.50
2026-07-20	ROIV	34.07	-42.2	-	-1.50
2026-07-21	ROIV	34.95	-42.2	-	-1.50
2026-07-22	ROIV	34.91	-42.2	-	-1.50
2026-07-23	ROIV	35.09	-42.2	-	-1.50
2026-07-24	ROIV	35.03	-42.2	-	-1.50
2026-07-27	ROIV	34.70	-42.2	-	-1.50
2026-07-28	ROIV	33.83	-42.2	-	-1.50
2026-07-29	ROIV	32.87	-42.2	-	-1.50
2026-07-30	ROIV	34.51	-42.2	-	-1.50
2026-07-31	ROIV	33.91	-42.2	-	-1.50
2026-08-03	ROIV	33.31	-42.2	-	-1.50
2026-08-04	ROIV	33.31	-42.2	-	-1.50
2026-08-05	ROIV	34.60	-42.2	-	-1.50
2026-08-06	ROIV	35.11	-42.2	-	-1.50
2026-08-07	ROIV	36.33	-42.2	-	-1.50
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-07-14	ROIV	-6.57	4.57	6.42
2026-07-15	ROIV	-6.48	4.57	6.42
2026-07-16	ROIV	-6.48	4.57	6.42
2026-07-17	ROIV	-6.48	4.57	6.42
2026-07-20	ROIV	-6.48	4.77	6.42
2026-07-21	ROIV	-6.48	4.77	6.42
2026-07-22	ROIV	-6.48	4.77	6.42
2026-07-23	ROIV	-6.48	4.77	6.42
2026-07-24	ROIV	-6.48	4.77	6.42
2026-07-27	ROIV	-6.48	4.80	7.09
2026-07-28	ROIV	-6.48	4.80	7.09
2026-07-29	ROIV	-6.48	4.80	7.09
2026-07-30	ROIV	-6.57	4.80	7.09
2026-07-31	ROIV	-6.57	4.80	7.09
2026-08-03	ROIV	-6.54	5.06	5.89
2026-08-04	ROIV	-12.50	5.06	5.89
2026-08-05	ROIV	-12.50	5.06	5.89
2026-08-06	ROIV	-12.50	5.06	5.89
2026-08-07	ROIV	-12.50	5.06	5.89
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.36

Avg. EPS Est. Next Quarter

-0.4

Insider Transactions

-12.5

Institutional Transactions

5.06

Beta

1.12

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

1.8

Max Drawdown 5-Year %

Target Price

41.27

P/E

Forward P/E

PEG

P/S

3485.39

P/B

6.2

P/Free Cash Flow

EPS

-0.44

Average EPS Est. Cur. Y

-1.5

EPS Next Y. (Est.)

-1.56

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-3534.96

Relative Volume

1.12

Return on Equity vs Sector %

-33.6

Return on Equity vs Industry %

-17.5

EPS 1 7Days Diff

-0.3

EPS 1 30Days Diff

-0.34

EBIT Estimation

◆ ROIV Healthcare

$36.33

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

20/20

Pullback

10/25

Volume

4/15

Valuation

4/20

TP/AR

4/10

Options

7/10

RSI

62.1

Range 1M

83.1%

Sup Dist

7.2%

🚀

Momentum Growth

Ride accelerating trends

N/A

WATCH

Momentum

21/25

Growth

10/30

Estimates

3/20

Inst/Vol

11/15

Options

10/10

EPS Yr

-150.6%

EPS NY

11.7%

52W%

97.1%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟡 HOLD +13.6% upside

Quality

6/30

Valuation

4/30

Growth

6/25

Stability

7/10

LT Trend

4/5

Upside

+13.6%

Quality

ROIV — P/E HistoricalBiotechnology

Roivant Sciences Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 721

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

ROIV

Latest News

—

Caricamento notizie per ROIV…

stock quote shares ROIV – Roivant Sciences Ltd Stock Price stock today

news today ROIV – Roivant Sciences Ltd stock forecast ,stock prediction 2023 2024 2025

marketwatch ROIV – Roivant Sciences Ltd yahoo finance google finance

stock history ROIV – Roivant Sciences Ltd invest stock market

stock prices ROIV premarket after hours

ticker ROIV fair value insiders trading

RNAM – Avidity Biosciences Inc

ONC – BeOne Medicines Ltd ADR

ONC — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

0.91

Margin Of Safety %

-20

Put/Call OI Ratio

0.65

EPS Next Q Diff

-0.31

EPS Last/This Y

-1.52

EPS This/Next Y

3.15

Price

348.31

Target Price

426.91

Analyst Recom

1.18

Performance Q

9.86

Upside

-42.8%

Beta

0.5

Ticker: ONC

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-07-14	ONC	306.37	0.74	0.18	2353
2026-07-15	ONC	311.3	0.74	0.50	2358
2026-07-16	ONC	317.24	0.74	0.83	2361
2026-07-17	ONC	312.31	0.74	0.67	2361
2026-07-20	ONC	310.64	0.74	9.00	2175
2026-07-21	ONC	318.87	0.76	0.45	2203
2026-07-22	ONC	320.01	0.75	1.00	2235
2026-07-23	ONC	326.48	0.74	0.00	2248
2026-07-24	ONC	325.64	0.74	0.83	2257
2026-07-27	ONC	325.84	0.74	0.43	2259
2026-07-28	ONC	330.28	0.74	2.00	2261
2026-07-29	ONC	327.14	0.74	0.00	2267
2026-07-30	ONC	321.9	0.75	0.04	2262
2026-07-31	ONC	315.74	0.61	0.00	2598
2026-08-03	ONC	313.87	0.61	0.44	2598
2026-08-04	ONC	323.21	0.61	0.11	2612
2026-08-05	ONC	327.36	0.62	0.91	2577
2026-08-06	ONC	330.12	0.65	0.19	2887
2026-08-07	ONC	348.25	0.65	3.63	2900
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-07-14	ONC	306.32	77.5	80.3	6.43
2026-07-15	ONC	310.93	77.5	91.6	6.43
2026-07-16	ONC	317.71	80.9	97.9	6.44
2026-07-17	ONC	311.82	80.9	71.8	6.44
2026-07-20	ONC	312.02	80.9	100.6	6.44
2026-07-21	ONC	318.66	80.9	94.5	6.44
2026-07-22	ONC	319.58	80.9	83.1	6.44
2026-07-23	ONC	327.90	80.9	91.6	6.44
2026-07-24	ONC	326.87	80.9	102.0	6.44
2026-07-27	ONC	326.94	87.4	81.1	6.44
2026-07-28	ONC	330.14	89.7	86.6	6.47
2026-07-29	ONC	326.90	89.7	100.0	6.47
2026-07-30	ONC	322.86	92.7	70.8	6.55
2026-07-31	ONC	315.72	92.7	66.5	6.55
2026-08-03	ONC	313.45	94.2	69.5	6.54
2026-08-04	ONC	313.45	94.2	69.5	6.54
2026-08-05	ONC	327.51	94.2	109.3	6.54
2026-08-06	ONC	329.63	94.2	102.4	6.54
2026-08-07	ONC	348.31	94.2	-80.1	6.54
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-07-14	ONC	-7.18	-0.48	0.78
2026-07-15	ONC	-31.73	-0.48	0.78
2026-07-16	ONC	-31.73	-0.48	0.78
2026-07-17	ONC	-31.73	-0.48	0.78
2026-07-20	ONC	-52.80	-0.49	0.78
2026-07-21	ONC	-52.80	-0.49	0.78
2026-07-22	ONC	-52.80	-0.49	0.78
2026-07-23	ONC	-56.98	-0.49	0.78
2026-07-24	ONC	-56.98	-0.49	0.78
2026-07-27	ONC	-57.04	-0.67	0.91
2026-07-28	ONC	-57.04	-0.67	0.91
2026-07-29	ONC	-57.04	-0.67	0.91
2026-07-30	ONC	-57.04	-0.67	0.91
2026-07-31	ONC	-57.04	-0.67	0.91
2026-08-03	ONC	-57.04	-0.63	0.91
2026-08-04	ONC	-57.08	-0.63	0.91
2026-08-05	ONC	-57.12	-0.63	0.91
2026-08-06	ONC	-57.12	-0.63	0.91
2026-08-07	ONC	-57.06	-0.63	0.91
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

2.05

Avg. EPS Est. Current Quarter

1.63

Avg. EPS Est. Next Quarter

1.74

Insider Transactions

-57.06

Institutional Transactions

-0.63

Beta

0.5

Average Sales Estimate Current Quarter

1594

Average Sales Estimate Next Quarter

1678

Fair Value

277.52

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

18.3

Max Drawdown 5-Year %

-70

Target Price

426.91

P/E

61.2

Forward P/E

35.41

PEG

0.5

P/S

5.8

P/B

7.61

P/Free Cash Flow

26.72

EPS

5.69

Average EPS Est. Cur. Y

6.54

EPS Next Y. (Est.)

9.69

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

10.7

Relative Volume

Return on Equity vs Sector %

-14.6

Return on Equity vs Industry %

1.4

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

-0.05

EBIT Estimation

-80.1

◆ ONC Healthcare

$348.27

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

20/20

Pullback

4/25

Volume

3/15

Valuation

13/20

TP/AR

2/10

Options

6/10

RSI

73.2

Range 1M

91.2%

Sup Dist

6.4%

🚀

Momentum Growth

Ride accelerating trends

WATCH

Momentum

18/25

Growth

28/30

Estimates

5/20

Inst/Vol

5/15

Options

3/10

EPS Yr

170.8%

EPS NY

38.1%

52W%

69.4%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🔴 SELL -2.9% upside

Quality

15/30

Valuation

2/30

Growth

20/25

Stability

4/10

LT Trend

4/5

Upside

-2.9%

Quality

MoS

-20%

ONC — P/E HistoricalBiotechnology

BeOne Medicines Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 12000

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

ONC

Latest News

—

Caricamento notizie per ONC…

stock quote shares ONC – BeOne Medicines Ltd ADR Stock Price stock today

news today ONC – BeOne Medicines Ltd ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch ONC – BeOne Medicines Ltd ADR yahoo finance google finance

stock history ONC – BeOne Medicines Ltd ADR invest stock market

stock prices ONC premarket after hours

ticker ONC fair value insiders trading

COGT – Cogent Biosciences Inc

COGT — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

11.15

Margin Of Safety %

Put/Call OI Ratio

0.23

EPS Next Q Diff

-0.04

EPS Last/This Y

-0.1

EPS This/Next Y

1.31

Price

42.36

Target Price

54.25

Analyst Recom

1.31

Performance Q

21.85

Upside

-308.1%

Beta

0.33

Ticker: COGT

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-07-14	COGT	38.52	0.26	0.88	22577
2026-07-15	COGT	39.3	0.26	0.71	22621
2026-07-16	COGT	37.94	0.26	1.81	22627
2026-07-17	COGT	39.06	0.26	0.37	22741
2026-07-20	COGT	38.29	0.27	0.47	20911
2026-07-21	COGT	39.64	0.27	0.61	21075
2026-07-22	COGT	39.58	0.27	3.01	21303
2026-07-23	COGT	40.25	0.29	1.82	21608
2026-07-24	COGT	39.74	0.29	0.21	21681
2026-07-27	COGT	40.46	0.29	0.01	21706
2026-07-28	COGT	40.65	0.29	0.12	21686
2026-07-29	COGT	39.55	0.29	3.71	21715
2026-07-30	COGT	41.38	0.29	0.19	21667
2026-07-31	COGT	38.91	0.29	3.14	21667
2026-08-03	COGT	38.81	0.30	5.54	21837
2026-08-04	COGT	42.82	0.31	0.03	22087
2026-08-05	COGT	42.27	0.24	0.29	27380
2026-08-06	COGT	41.77	0.23	0.02	28858
2026-08-07	COGT	42.39	0.23	0.02	28849
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-07-14	COGT	38.51	-6.6	-	-2.26
2026-07-15	COGT	39.32	-6.6	-	-2.26
2026-07-16	COGT	37.94	-6.6	-	-2.26
2026-07-17	COGT	39.07	-6.6	-	-2.26
2026-07-20	COGT	38.31	-6.6	-	-2.26
2026-07-21	COGT	39.65	-6.6	-	-2.26
2026-07-22	COGT	39.56	-6.6	-	-2.26
2026-07-23	COGT	40.24	-6.6	-	-2.26
2026-07-24	COGT	39.74	-6.6	-	-2.26
2026-07-27	COGT	40.45	-6.6	-	-2.26
2026-07-28	COGT	40.67	-6.6	-	-2.26
2026-07-29	COGT	39.58	-6.6	-	-2.26
2026-07-30	COGT	41.38	-6.6	-	-2.26
2026-07-31	COGT	38.90	-6.6	-	-2.26
2026-08-03	COGT	38.86	-6.6	-	-2.26
2026-08-04	COGT	38.86	-6.6	-	-2.26
2026-08-05	COGT	42.29	-6.6	-	-2.26
2026-08-06	COGT	41.78	-6.6	-	-2.26
2026-08-07	COGT	42.36	-6.6	-	-2.26
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-07-14	COGT	-31.93	7.92	11.01
2026-07-15	COGT	-31.93	7.92	11.01
2026-07-16	COGT	-31.93	7.92	11.01
2026-07-17	COGT	-31.93	7.92	11.01
2026-07-20	COGT	-31.93	8.11	11.01
2026-07-21	COGT	-31.93	8.11	11.01
2026-07-22	COGT	-31.93	8.11	11.01
2026-07-23	COGT	-23.82	8.11	11.01
2026-07-24	COGT	-23.82	8.11	11.01
2026-07-27	COGT	-23.82	7.99	11.15
2026-07-28	COGT	-23.82	7.99	11.15
2026-07-29	COGT	-23.82	7.99	11.15
2026-07-30	COGT	-23.82	7.99	11.15
2026-07-31	COGT	-23.82	7.99	11.15
2026-08-03	COGT	-23.82	1.93	11.15
2026-08-04	COGT	-23.82	1.93	11.15
2026-08-05	COGT	-23.82	1.93	11.15
2026-08-06	COGT	-23.82	1.93	11.15
2026-08-07	COGT	-23.82	1.93	11.15
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.53

Avg. EPS Est. Current Quarter

-0.56

Avg. EPS Est. Next Quarter

-0.57

Insider Transactions

-23.82

Institutional Transactions

1.93

Beta

0.33

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

3.1

Max Drawdown 5-Year %

-76.3

Target Price

54.25

P/E

Forward P/E

PEG

P/S

P/B

13.34

P/Free Cash Flow

EPS

-2.52

Average EPS Est. Cur. Y

-2.26

EPS Next Y. (Est.)

-0.94

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.75

Return on Equity vs Sector %

-85.6

Return on Equity vs Industry %

-69.5

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

◆ COGT Healthcare

$42.39

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

0/20

Pullback

8/25

Volume

6/15

Valuation

6/20

TP/AR

2/10

Options

8/10

RSI

60.8

Range 1M

81.5%

Sup Dist

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

7/25

Growth

13/30

Estimates

0/20

Inst/Vol

7/15

Options

8/10

EPS Yr

-3.9%

EPS NY

65.6%

52W%

95.4%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟡 HOLD +28% upside

Quality

2/30

Valuation

6/30

Growth

9/25

Stability

7/10

LT Trend

1/5

Upside

+28%

Quality

COGT — P/E HistoricalBiotechnology

Cogent Biosciences, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 258

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

COGT

Latest News

—

Caricamento notizie per COGT…

stock quote shares COGT – Cogent Biosciences Inc Stock Price stock today

news today COGT – Cogent Biosciences Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch COGT – Cogent Biosciences Inc yahoo finance google finance

stock history COGT – Cogent Biosciences Inc invest stock market

stock prices COGT premarket after hours

ticker COGT fair value insiders trading

CGON – Cg Oncology Inc

CGON — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

21.2

Margin Of Safety %

Put/Call OI Ratio

0.15

EPS Next Q Diff

0.03

EPS Last/This Y

-0.59

EPS This/Next Y

-0.08

Price

75.11

Target Price

91.08

Analyst Recom

1.13

Performance Q

8.56

Upside

-179.1%

Beta

0.24

Ticker: CGON

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-07-14	CGON	71.67	0.33	0.09	65523
2026-07-15	CGON	73.03	0.33	0.19	65535
2026-07-16	CGON	69.93	0.33	0.04	66147
2026-07-17	CGON	71.89	0.33	0.00	66943
2026-07-20	CGON	70.27	0.15	0.07	18845
2026-07-21	CGON	71.77	0.14	0.05	19545
2026-07-22	CGON	69.28	0.14	2.49	19658
2026-07-23	CGON	71.06	0.15	0.13	19777
2026-07-24	CGON	69.31	0.15	1.04	19891
2026-07-27	CGON	73.49	0.15	0.13	20043
2026-07-28	CGON	72.69	0.15	1.91	20438
2026-07-29	CGON	68.7	0.16	0.23	20599
2026-07-30	CGON	73.03	0.16	0.88	20631
2026-07-31	CGON	71.18	0.16	0.02	20683
2026-08-03	CGON	69.07	0.16	0.90	20660
2026-08-04	CGON	71.39	0.16	0.02	20708
2026-08-05	CGON	72.32	0.16	0.12	21538
2026-08-06	CGON	74.75	0.16	0.11	21820
2026-08-07	CGON	75.09	0.15	0.10	22631
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-07-14	CGON	71.76	-18.8	-68.3	-2.66
2026-07-15	CGON	73.06	-18.8	-78.1	-2.66
2026-07-16	CGON	69.51	-18.8	-55.0	-2.66
2026-07-17	CGON	71.82	-18.8	-83.5	-2.66
2026-07-20	CGON	70.21	-18.8	-63.6	-2.66
2026-07-21	CGON	71.77	-18.8	-79.6	-2.66
2026-07-22	CGON	69.32	-18.8	-60.1	-2.66
2026-07-23	CGON	71.10	-18.8	-81.0	-2.66
2026-07-24	CGON	69.33	-18.8	-63.1	-2.66
2026-07-27	CGON	73.50	-19.0	-92.9	-2.67
2026-07-28	CGON	72.62	-19.0	-67.8	-2.67
2026-07-29	CGON	69.22	-19.0	-55.7	-2.67
2026-07-30	CGON	73.05	-19.0	-91.6	-2.67
2026-07-31	CGON	71.21	-19.0	-63.3	-2.67
2026-08-03	CGON	69.06	-19.0	-61.4	-2.67
2026-08-04	CGON	69.06	-19.0	-61.4	-2.67
2026-08-05	CGON	72.32	-19.0	-76.8	-2.67
2026-08-06	CGON	74.73	-19.0	-83.3	-2.67
2026-08-07	CGON	75.11	-19.0	-73.1	-2.67
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-07-14	CGON	1.11	2.24	21.14
2026-07-15	CGON	1.03	2.24	21.14
2026-07-16	CGON	1.03	2.24	21.14
2026-07-17	CGON	1.03	2.24	21.14
2026-07-20	CGON	1.02	2.21	21.14
2026-07-21	CGON	1.02	2.21	21.14
2026-07-22	CGON	1.02	2.21	21.14
2026-07-23	CGON	1.02	2.21	21.14
2026-07-24	CGON	1.02	2.21	21.14
2026-07-27	CGON	1.02	2.23	21.20
2026-07-28	CGON	1.02	2.23	21.20
2026-07-29	CGON	1.02	2.23	21.20
2026-07-30	CGON	1.02	2.23	21.20
2026-07-31	CGON	1.02	2.23	21.20
2026-08-03	CGON	1.02	4.16	21.20
2026-08-04	CGON	1.02	4.16	21.20
2026-08-05	CGON	1.02	4.16	21.20
2026-08-06	CGON	1.02	4.16	21.20
2026-08-07	CGON	1.02	4.16	21.20
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.71

Avg. EPS Est. Current Quarter

-0.64

Avg. EPS Est. Next Quarter

-0.68

Insider Transactions

1.02

Institutional Transactions

4.16

Beta

0.24

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

2.5

Max Drawdown 5-Year %

Target Price

91.08

P/E

Forward P/E

PEG

P/S

1063.24

P/B

6.44

P/Free Cash Flow

EPS

-2.7

Average EPS Est. Cur. Y

-2.67

EPS Next Y. (Est.)

-2.75

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-3602.68

Relative Volume

0.58

Return on Equity vs Sector %

-44.4

Return on Equity vs Industry %

-28.3

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.02

EBIT Estimation

-73.1

◆ CGON Healthcare

$75.10

📉

Swing / Pullback

Buy the dip on strong trends

WATCH

Trend

20/20

Pullback

8/25

Volume

11/15

Valuation

6/20

TP/AR

4/10

Options

7/10

RSI

58.4

Range 1M

79.5%

Sup Dist

3.7%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

12/25

Growth

5/30

Estimates

3/20

Inst/Vol

6/15

Options

10/10

EPS Yr

-55.3%

EPS NY

7.5%

52W%

95.5%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟡 HOLD +21.3% upside

Quality

2/30

Valuation

6/30

Growth

3/25

Stability

8/10

LT Trend

4/5

Upside

+21.3%

Quality

CGON — P/E HistoricalBiotechnology

CG Oncology, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 142

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.

CGON

Latest News

—

Caricamento notizie per CGON…

stock quote shares CGON – Cg Oncology Inc Stock Price stock today

news today CGON – Cg Oncology Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch CGON – Cg Oncology Inc yahoo finance google finance

stock history CGON – Cg Oncology Inc invest stock market

stock prices CGON premarket after hours

ticker CGON fair value insiders trading

No more stocks to show

PBLS – Parabilis Medicines Inc

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: PBLS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

ROIV – Roivant Sciences Ltd

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ROIV

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y